{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Brunnert D"],"funding":["Deutsche Forschungsgemeinschaft","Department of Biotechnology","Indian Council of Medical Research"],"pagination":["1181"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10459547"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(8)"],"pubmed_abstract":["The <i>N</i>,<i>C</i>-coupled naphthylisoquinoline alkaloid ancistrocladinium A belongs to a novel class of natural products with potent antiprotozoal activity. Its effects on tumor cells, however, have not yet been explored. We demonstrate the antitumor activity of ancistrocladinium A in multiple myeloma (MM), a yet incurable blood cancer that represents a model disease for adaptation to proteotoxic stress. Viability assays showed a potent apoptosis-inducing effect of ancistrocladinium A in MM cell lines, including those with proteasome inhibitor (PI) resistance, and in primary MM cells, but not in non-malignant blood cells. Concomitant treatment with the PI carfilzomib or the histone deacetylase inhibitor panobinostat strongly enhanced the ancistrocladinium A-induced apoptosis. Mass spec"],"journal":["Pharmaceuticals (Basel, Switzerland)"],"pubmed_title":["Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate."],"pmcid":["PMC10459547"],"funding_grant_id":["BT/INF/22/SP44383/2021","BT/HRD/01/59/2020","KFO216","6/9-7(234)2020/ECD-II"],"pubmed_authors":["Seupel R","Bach M","Schlosser A","Bringmann G","Bargou RC","Kirner S","Chatterjee M","Goyal P","Schraud H","Koster E","Feineis D","Brunnert D"],"additional_accession":[]},"is_claimable":false,"name":"Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate.","description":"The <i>N</i>,<i>C</i>-coupled naphthylisoquinoline alkaloid ancistrocladinium A belongs to a novel class of natural products with potent antiprotozoal activity. Its effects on tumor cells, however, have not yet been explored. We demonstrate the antitumor activity of ancistrocladinium A in multiple myeloma (MM), a yet incurable blood cancer that represents a model disease for adaptation to proteotoxic stress. Viability assays showed a potent apoptosis-inducing effect of ancistrocladinium A in MM cell lines, including those with proteasome inhibitor (PI) resistance, and in primary MM cells, but not in non-malignant blood cells. Concomitant treatment with the PI carfilzomib or the histone deacetylase inhibitor panobinostat strongly enhanced the ancistrocladinium A-induced apoptosis. Mass spec","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2026-04-08T13:39:54.765Z","creation":"2025-04-19T10:18:04.881Z"},"accession":"S-EPMC10459547","cross_references":{"pubmed":["37631095"],"doi":["10.3390/ph16081181"]}}